Shrimanker, R., Pavord, I., Price, R., Bradford, E., Keene, O., & Yancey, S. (2018). Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma. American Thoracic Society.
Chicago Style (17th ed.) CitationShrimanker, R., I. Pavord, R. Price, E. Bradford, O. Keene, and S. Yancey. Fractional Exhaled Nitric Oxide and the Peripheral Blood Eosinophil Count as Biomarkers of the Response to Mepolizumab in Patients with Severe Eosinophilic Asthma. American Thoracic Society, 2018.
MLA citiranjeShrimanker, R., et al. Fractional Exhaled Nitric Oxide and the Peripheral Blood Eosinophil Count as Biomarkers of the Response to Mepolizumab in Patients with Severe Eosinophilic Asthma. American Thoracic Society, 2018.